a developer of pharmaceutical drugs for treating cancer and inflammatory diseases
Industry Biotechnology
A.I.dvisor tells us that CASI and RIGL have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and RIGL's prices will move in lockstep.
Ticker / NAME | Correlation To CASI | 1D Price Change % | ||
---|---|---|---|---|
CASI | 100% | -1.37% | ||
RIGL - CASI | 30% Poorly correlated | -2.38% | ||
ONCO - CASI | 25% Poorly correlated | -5.15% | ||
ATRA - CASI | 24% Poorly correlated | -10.39% | ||
IMRX - CASI | 21% Poorly correlated | +9.01% | ||
ADAG - CASI | 20% Poorly correlated | +7.50% | ||
More |
Ticker / NAME | Correlation To CASI | 1D Price Change % |
---|---|---|
CASI | 100% | -1.37% |
inflammation theme (11 stocks) | 21% Poorly correlated | +0.92% |
cancer theme (87 stocks) | 13% Poorly correlated | +0.89% |
pharmaceuticals theme (167 stocks) | 12% Poorly correlated | +0.82% |
drugs theme (265 stocks) | 9% Poorly correlated | +5.37% |
biotechnology theme (248 stocks) | 9% Poorly correlated | +5.56% |